Cargando…

Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12

There is strong evidence that chemotherapy can induce tumor necrosis which can be exploited for the targeted delivery of immuno-oncology agents into the tumor microenvironment (TME). We hypothesized that docetaxel, a chemotherapeutic agent that induces necrosis, in combination with the bifunctional...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franks, S. Elizabeth, Santiago-Sanchez, Ginette S., Fabian, Kellsye P., Solocinski, Kristen, Chariou, Paul L., Hamilton, Duane H., Kowalczyk, Joshua T., Padget, Michelle R., Gameiro, Sofia R., Schlom, Jeffrey, Hodge, James W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361896/ https://www.ncbi.nlm.nih.gov/pubmed/37166485 http://dx.doi.org/10.1007/s00262-023-03459-7

Ejemplares similares

Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
por: Fabian, Kellsye P, et al.
Publicado: (2021)

Overcoming hypoxia-induced functional suppression of NK cells
por: Solocinski, Kristen, et al.
Publicado: (2020)

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
por: Fabian, Kellsye P, et al.
Publicado: (2020)

Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies
por: Kowalczyk, Joshua T, et al.
Publicado: (2022)

Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models
por: Franks, S. Elizabeth, et al.
Publicado: (2022)

Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing
por: Wolfson, Benjamin, et al.
Publicado: (2021)

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
por: Minnar, Christine M, et al.
Publicado: (2022)

Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation
por: Santiago-Sánchez, Ginette S., et al.
Publicado: (2022)

Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication
por: Horn, Lucas A., et al.
Publicado: (2022)

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
por: Robbins, Yvette, et al.
Publicado: (2020)

From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment
por: Fabian, Kellsye P., et al.
Publicado: (2021)

Dying of Stress: Chemotherapy, Radiotherapy, and Small-Molecule Inhibitors in Immunogenic Cell Death and Immunogenic Modulation
por: Fabian, Kellsye P., et al.
Publicado: (2022)

Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies
por: Friedman, Jay, et al.
Publicado: (2018)

Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies
por: Lui, Grace, et al.
Publicado: (2023)

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation
por: Hodge, James W, et al.
Publicado: (2013)

Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment
por: Maldonado, Maria del Mar, et al.
Publicado: (2023)

The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy
por: Fabian, Kellsye P., et al.
Publicado: (2021)

Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa
por: Ozawa, Yohei, et al.
Publicado: (2021)

Combinatorial Natural Killer Cell–based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells
por: Hoke, Austin T.K., et al.
Publicado: (2021)

Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody
por: Hamilton, Duane H., et al.
Publicado: (2014)

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape
por: Hicks, Kristin C., et al.
Publicado: (2021)

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine
por: Hamilton, Duane H., et al.
Publicado: (2013)

Brachyury, a driver of tumor invasiveness and resistance to multiple therapies, is a novel immunotherapy target
por: Palena, Claudia, et al.
Publicado: (2013)

Upregulation of oncogenic MUC1 by the EMT transcription factor brachyury mediates immunotherapy-resistance in tumor cells
por: David, Justin M, et al.
Publicado: (2015)

Therapeutic Use of Dendritic Cells to Promote the Extranodal Priming of Anti-Tumor Immunity
por: Chen, Lu, et al.
Publicado: (2013)

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
por: Knudson, Karin M., et al.
Publicado: (2018)

Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL
por: Jochems, Caroline, et al.
Publicado: (2015)

Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy
por: Horn, Lucas A., et al.
Publicado: (2021)

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
por: Hicks, Kristin C., et al.
Publicado: (2018)

Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
por: Fenerty, Kathleen E., et al.
Publicado: (2018)

Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition
por: Fenerty, Kathleen E., et al.
Publicado: (2019)

Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing
por: Gameiro, Sofia R., et al.
Publicado: (2013)

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
por: Horn, Lucas A, et al.
Publicado: (2020)

Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression
por: Harris, Alexandra R., et al.
Publicado: (2018)

The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance
por: David, Justin, et al.
Publicado: (2014)

Combination therapies utilizing neoepitope-targeted vaccines
por: Lee, Karin L., et al.
Publicado: (2020)

Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor
Publicado: (1986)

Triggered Drug Release From Liposomes: Exploiting the Outer and Inner Tumor Environment
por: Franco, Marina Santiago, et al.
Publicado: (2021)

Development of docetaxel nanocrystals surface modified with transferrin for tumor targeting
por: Choi, Jin-Seok, et al.
Publicado: (2016)

Exploiting tumor cell senescence in anticancer therapy
por: Lee, Minyoung, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_n3bn9v4qvltussauklj3hhnj76